Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 2020Website:
http://www.iteostherapeutics.comNext earnings report:
06 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:43:40 GMTDividend
Analysts recommendations
Institutional Ownership
ITOS Latest News
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval.
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain.
ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.96 per share a year ago.
WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies.
iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to differentiate from other anti-TIGIT approaches, with positive interim data readouts. Financially, ITOS has a strong balance sheet with significant cash reserves, but faces risks from unproven TIGIT targets and market valuation fluctuations.
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
iTeos Therapeutics, Inc. (ITOS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
What type of business is iTeos Therapeutics?
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
What sector is iTeos Therapeutics in?
iTeos Therapeutics is in the Healthcare sector
What industry is iTeos Therapeutics in?
iTeos Therapeutics is in the Biotechnology industry
What country is iTeos Therapeutics from?
iTeos Therapeutics is headquartered in United States
When did iTeos Therapeutics go public?
iTeos Therapeutics initial public offering (IPO) was on 24 July 2020
What is iTeos Therapeutics website?
https://www.iteostherapeutics.com
Is iTeos Therapeutics in the S&P 500?
No, iTeos Therapeutics is not included in the S&P 500 index
Is iTeos Therapeutics in the NASDAQ 100?
No, iTeos Therapeutics is not included in the NASDAQ 100 index
Is iTeos Therapeutics in the Dow Jones?
No, iTeos Therapeutics is not included in the Dow Jones index
When was iTeos Therapeutics the previous earnings report?
No data
When does iTeos Therapeutics earnings report?
The next expected earnings date for iTeos Therapeutics is 06 March 2025